Apr 20, 2026 at 8:23 AM#2
Excellent question, and yes, there are meaningful differences from a compounding perspective:
Molecular Complexity:
- Semaglutide: 31 amino acids, molecular weight ~4,114 Da
- Tirzepatide: 39 amino acids, molecular weight ~4,810 Da
Tirzepatide is a larger, more complex peptide with a dual-action mechanism (GIP + GLP-1 receptor agonist). This additional complexity has implications:
Stability:
- Tirzepatide is generally considered LESS stable in solution than semaglutide
- More susceptible to aggregation at higher concentrations
- More sensitive to pH deviations — optimal stability is in a narrower pH range
- The fatty acid side chain (C20) in tirzepatide is different from semaglutide's (C18), affecting formulation compatibility
- Some compounders report more lot-to-lot variability with tirz formulations
Formulation Challenges:
- Tirzepatide can be more difficult to get into solution at higher concentrations
- Requires more careful buffer selection
- More prone to adsorption onto container surfaces (which can reduce effective concentration)
- Some preservative systems that work well with sema may interact differently with tirz
Beyond-Use Dating:
- Given the stability differences, BUDs for compounded tirz tend to be shorter than sema
- A compounder who assigns a 90-day BUD for their semaglutide should NOT automatically apply the same BUD to their tirzepatide without separate stability data
Last edited: Apr 20, 2026 at 10:23 AM
43 13PedsEndoPhilly, SleepDoc_PDX, RegAffairsDC and 40 others
Reply Quote Save Share Report